clinical trial · NCT06130345
Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran
ModernaTX, Inc.·—·completed·n = 15,196,685
SARS-CoV-2SPIKEVAX
brief summary
The main objective of the study is to evaluate the safety of the elasomeran/davesomeran and andusomeran vaccines as used in routine clinical practice.
started
Apr 14, 2023
primary completion
Feb 29, 2024
completion
Aug 31, 2024
last updated
Dec 19, 2024
official title
Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran Vaccines in the United States
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol